Advertisement

Topics

Janssen’s Plivensia given thumbs down by US advisors

06:06 EDT 3 Aug 2017 | PharmaTimes

US regulatory advisors are not recommending approval of Johnson & Johnson’s Plivensia for rheumatoid arthritis, having concluded - based on the data available - that the benefits of the drug do not outweigh the potential risks.

Original Article: Janssen’s Plivensia given thumbs down by US advisors

NEXT ARTICLE

More From BioPortfolio on "Janssen’s Plivensia given thumbs down by US advisors"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...